Actinium Pharmaceuticals (ATNM) Share-based Compensation (2012 - 2026)
Actinium Pharmaceuticals (ATNM) posted quarterly Share-based Compensation of $100000.0 for Q1 2026, down 98.87% year-over-year from $8.9 million in Q1 2025, and up 900.0% quarter-over-quarter from $10000.0 in Q4 2025.
Actinium Pharmaceuticals (ATNM) Share-based Compensation (2012 - 2026) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Share-based Compensation for 15 consecutive years, with $100000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 98.87% year-over-year to $100000.0; the TTM figure through Mar 2026 stood at $100000.0 (down 99.22% YoY), while the FY2025 annual figure was $9.2 million, up 0.99% from the prior year.
- Share-based Compensation rose to $100000.0 in Q1 2026 per ATNM's latest filing, from $10000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $8.9 million in Q1 2025 and bottomed at $10000.0 in Q4 2025.
- Historically, Share-based Compensation has averaged $1.2 million across 5 years, with a median of $970000.0 in 2022.
- On a YoY basis, Share-based Compensation climbed as much as 543.98% in 2025 and fell as far as 99.17% in 2025.
- Actinium Pharmaceuticals' Share-based Compensation stood at $979000.0 in 2022, then fell by 5.31% to $927000.0 in 2023, then advanced by 29.77% to $1.2 million in 2024, then sank by 99.17% to $10000.0 in 2025, then surged by 900.0% to $100000.0 in 2026.
- Business Quant data shows ATNM's Share-based Compensation at $100000.0 in Q1 2026, $10000.0 in Q4 2025, and $100000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.64 Bn | 130.78 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.90 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.11 Bn | 59.93 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.83 Bn | 50.69 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.01 Bn | 36.91 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.63 Bn | 28.32 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 27.65 Bn | 9.26 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - | - |
| 10 | Actinium Pharmaceuticals | 34.85 Mn | 34.85 Mn | - | 300,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 300,000.00 |
| Jun 30, 2026 | 300,000.00 |
| Mar 31, 2026 | 100,000.00 |
| Mar 31, 2026 | 100,000.00 |
| Dec 31, 2025 | 10,000.00 |
| Dec 31, 2025 | 10,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 197,000.00 |
| Jun 30, 2025 | 197,000.00 |
| Mar 31, 2025 | 8.87 Mn |
| Mar 31, 2025 | 8.87 Mn |
| Dec 31, 2024 | 1.20 Mn |
| Dec 31, 2024 | 1.20 Mn |
| Sep 30, 2024 | 1.34 Mn |
| Sep 30, 2024 | 1.34 Mn |
| Jun 30, 2024 | 1.37 Mn |
| Jun 30, 2024 | 1.37 Mn |
| Mar 31, 2024 | 1.38 Mn |
| Mar 31, 2024 | 1.38 Mn |